http://rdf.ncbi.nlm.nih.gov/pubchem/reference/36331397

Outgoing Links

Predicate Object
contentType Journal Article
issn 2589-5370
pageRange 102131-
publicationName eClinicalMedicine
startingPage 102131
hasFundingAgency http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_81491a8acaee7bd5720ca469c51d1374
bibliographicCitation Zinzani PL, Trněný M, Ribrag V, Zilioli VR, Walewski J, Christensen JH, Delwail V, Rodriguez G, Venugopal P, Coleman M, Dartigeas C, Patti C, Pane F, Jurczak W, Taszner M, Paneesha S, Zheng F, DeMarini DJ, Jiang W, Gilmartin A, Mehta A. Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory mantle cell lymphoma (CITADEL-205): a phase 2 study. EClinicalMedicine. 2023 Aug;62():102131. PMID: 37599908; PMCID: PMC10433033.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1d953f8580ab8c22c628f992cd17695f
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_fa1afaa0e005acfd5df23d361694adba
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4d7ca4bbe9135750d8abe82a5b365015
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1411fadd1d04c6b6768616ca77e7220e
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_dc0e5f57bbbc8adea362ab70d35854be
http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-6952-6073
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e84d095d6854580b6066624106087d77
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ca6e06e888f7d9aaea156ce2b7bb04de
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_67c371724d6bad6c6f50e69b82838155
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_208af3396f1d71fecfa09c573a313ae2
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_44397345371545e5c7a29683bccdd930
http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-7446-011X
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3136a31350addb22c5b469631ed9bd41
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_20421d8ab0f34827712d7edebc0ede59
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_de90ec20dc2472204c94ebe03179871f
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_afd2bd92733ce538884ea08a6f69edf5
http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0003-1879-8084
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0a6fb0dc0193cb78bfb28fa9d2fac76f
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a9d531eaa1df40fa5182644c52e5e6c4
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_741734cd7dc29bb1028a5f74caeee1c9
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_47573050146a218946dc8a4e29021994
date 202308
identifier https://pubmed.ncbi.nlm.nih.gov/37599908
https://pubmed.ncbi.nlm.nih.gov/PMC10433033
https://doi.org/10.1016/j.eclinm.2023.102131
isPartOf https://portal.issn.org/resource/ISSN/2589-5370
http://rdf.ncbi.nlm.nih.gov/pubchem/journal/47998
language English
source https://pubmed.ncbi.nlm.nih.gov/
https://www.crossref.org/
title Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory mantle cell lymphoma (CITADEL-205): a phase 2 study
discussesAsDerivedByTextMining http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_c7be83279551b50c0e81dc2dbfe3c5d8
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_0c1bbc5947dc7d50c3960aba9470b9d4
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7507
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID10603
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID86677874
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8661
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8306
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_e2e9c6d37ebae8d49121718f1271bff2

Total number of triples: 46.